Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to intensive care~* Able to give informed consent by themselves or informed consent can be obtained via next of kin~* Indication for treatment with cefotaxime (as judged by treating physician) in the context of our standard treatment protocol of Selective decontamination of the digestive tract (SDD).~Exclusion Criteria:~* Renal replacement therapy~* Contra-indication for cefotaxime, including known or suspected allergy to cefotaxime~* No indication for an arterial line; an arterial line will not be placed solely for the purpose of this study; thus, only patients with an indication for an arterial line outside this protocol are eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent cefotaxime (Type: ACTIVE_COMPARATOR): Cefotaxime 1 gram (1000 mg) is to be administered 4 times daily for 4 days
- Continuous cefotaxime (Type: EXPERIMENTAL): After a 1 gram (1000 mg) Cefotaxime loading dose, Cefotaxime 4 gram (4000 mg) is to be administered as a continuous infusion in 24h for 4 days .

Based on this trial design, predict the completion outcome and termination type (if applicable).